Braveheart Bio, Attovia Therapeutics, and Vogenx announced on July 16 their plans to launch initial public offerings as they seek to advance pipelines in cardiovascular, immunology, and cardiometabolic therapies. The announcements follow a period of increased activity in the biotech sector, with public debuts this year already more than doubling last year's total.
The filings for all three companies are still early; none have specified fundraising targets or timelines for closing. Braveheart will list under the ticker BRVE on the Nasdaq Global Market, Attovia under ATTO, and Vogenx under VOGX. Their entries come after 18 biotechs went public in the first half of 2026—including record-setting raises by Kailera Therapeutics and Parabilis Medicines—and follow recent filings from Scribe Therapeutics and Kalohexis.
Investor interest has been buoyed by strong stock performances among newly listed biotechs as the XBI index approaches levels last seen during the pandemic. According to an investor note from Truist Securities dated July 7, hair loss company Veradermics is notable for its share price increase of over 600% since its February debut.
Braveheart is raising funds to support development of BHB-1893, a small-molecule cardiac myosin blocker licensed from Jiangsu Hengrui Pharmaceuticals for up to $1.1 billion. The company said it aims to position BHB-1893 as “a new standard of care” in hypertrophic cardiomyopathy (HCM), competing with Bristol Myers Squibb’s Camzyos—which generated $1.07 billion in sales last year—and Cytokinetics’ Myqorzo. Braveheart said clinical data show BHB-1893 produces “limited” reductions in left ventricular ejection fraction compared to existing treatments.
Attovia’s lead program is ATTO-1310 for chronic pruritus of unknown origin and high-itch atopic dermatitis (AD). The company said it seeks to address limitations such as inconvenient dosing and adverse events associated with current AD therapies like Sanofi and Regeneron’s Dupixent—which earned $17.8 billion last year—and plans further studies with another candidate targeting IL-13/IL-31 signaling pathways.
Vogenx focuses on diseases linked to dysfunctional metabolism; its main asset is mizagliflozin for post-bariatric hypoglycemia (PBH) and gastroparesis. According to its prospectus, competitors Amylyx Pharmaceuticals and Vanda Pharmaceuticals do not yet have FDA-approved candidates for these indications. Proceeds would also support preclinical work on VGX-2875 aimed at weight maintenance.
